Cell Stem Cell
Volume 28, Issue 2, 4 February 2021, Pages 343-355.e5
Journal home page for Cell Stem Cell

Resource
Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use

https://doi.org/10.1016/j.stem.2021.01.005Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Scalable and reproducible mDA neuron differentiation via biphasic WNT activation

  • EN1 is required to mediate effects of biphasic WNT activation

  • Protocol minimizes diencephalic, hindbrain, and non-neural contaminants

  • Cryopreserved mDA precursors yield A9 mDA neurons in vivo and rescue PD-rat model

Summary

Human pluripotent stem cells show considerable promise for applications in regenerative medicine, including the development of cell replacement paradigms for the treatment of Parkinson’s disease. Protocols have been developed to generate authentic midbrain dopamine (mDA) neurons capable of reversing dopamine-related deficits in animal models of Parkinson’s disease. However, the generation of mDA neurons at clinical scale suitable for human application remains an important challenge. Here, we present an mDA neuron derivation protocol based on a two-step WNT signaling activation strategy that improves expression of midbrain markers, such as Engrailed-1 (EN1), while minimizing expression of contaminating posterior (hindbrain) and anterior (diencephalic) lineage markers. The resulting neurons exhibit molecular, biochemical, and electrophysiological properties of mDA neurons. Cryopreserved mDA neuron precursors can be successfully transplanted into 6-hydroxydopamine (6OHDA) lesioned rats to induce recovery of amphetamine-induced rotation behavior. The protocol presented here is the basis for clinical-grade mDA neuron production and preclinical safety and efficacy studies.

Keywords

directed differentiation
human embryonic stem cells
human-induced pluripotent stem cells
neural patterning
WNT signaling
midbrain development
transplantation
Parkinson’s disease
cell therapy
preclinical study

Cited by (0)

10

Present address: Neurona Therapeutics, 170 Harbor Way, South San Francisco, CA 94080, USA

11

Present address: BlueRock Therapeutics, 430 East 29th Street, New York, NY 10016, USA

12

Present address: Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA

13

These authors contributed equally

14

Senior author

15

Lead Contact